Talphera Inc. (TLPH) is a Healthcare · Drug Manufacturers - Specialty & Generic company listed on NASDAQ. Price $1.16 (-0.85%), Market cap $0.05B, 52-week low–high $0.39 ~ $1.46.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pha
Financial statements, price targets, institutional (13F) holdings and related news for Talphera Inc. are updated in real time on BlackAll Trade.
Talphera Inc. trades at $1.16 (-0.85%). Real-time quotes and charts are available on BlackAll Trade.
Talphera Inc. has a market cap of about $0.05B.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad,